Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Global Life Sciences Conference (Transcript)
10:49pm, Tuesday, 09'th Mar 2021
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Global Life Sciences Conference (Transcript)
MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
05:00pm, Tuesday, 02'nd Mar 2021
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patient
MannKind Corporation: Bullish On High-Growth Inhaled Insulin Opportunity
02:07pm, Tuesday, 02'nd Mar 2021
MannKind Corp. develops inhaled therapeutic products including the only FDA-approved rapid-acting inhaled human insulin powder.
MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering
06:30am, Tuesday, 02'nd Mar 2021
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior
MannKind Corporation (MNKD) CEO Michael Castagna on Q4 2020 Results - Earnings Call Transcript
03:47pm, Thursday, 25'th Feb 2021
MannKind Corporation (MNKD) CEO Michael Castagna on Q4 2020 Results - Earnings Call Transcript
Why MannKind Corporation Stock Is Popping Today
02:57pm, Wednesday, 24'th Feb 2021
An analyst is excited about the company's prospects.
MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
05:00pm, Thursday, 18'th Feb 2021
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients
MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
09:00am, Thursday, 18'th Feb 2021
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a confe
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Bioconnect 2021 Brokers Conference (Transcript)
10:39am, Monday, 11'th Jan 2021
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Bioconnect 2021 Brokers Conference (Transcript)
MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference
05:00pm, Monday, 04'th Jan 2021
WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients
MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session
09:47am, Tuesday, 29'th Dec 2020
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium) Oral Solution
04:44pm, Thursday, 17'th Dec 2020
WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion a
James S. Shannon Transitions to Chairman of the Board of Directors for MannKind
08:00am, Thursday, 10'th Dec 2020
Kent Kresa, former Chairman, will continue to serve as a Director Kent Kresa, former Chairman, will continue to serve as a Director
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.
09:20am, Monday, 07'th Dec 2020
Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product Lead investigational product (inhaled clofazimine) designated by the
MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics
05:00pm, Thursday, 19'th Nov 2020
WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaborati
